These studies, among numerous others, show the importance of IFNs in the pathogenesis of SLE, which has led to research on biologics that target IFN, with the eventual development and use of Anifrolumab, a Type I IFN blocking antibody, in SLE. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.